Biocept, Inc., an early stage molecular oncology diagnostics company, develops and commercializes proprietary circulating tumor cell and circulating tumor DNA assays utilizing a standard blood sample. More Details
High growth potential with adequate balance sheet.
Share Price & News
How has Biocept's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: BIOC is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 14% a week.
Volatility Over Time: BIOC's weekly volatility has decreased from 32% to 14% over the past year, but is still higher than 75% of US stocks.
7 Day Return
1 Year Return
Return vs Industry: BIOC exceeded the US Biotechs industry which returned 36.8% over the past year.
Return vs Market: BIOC exceeded the US Market which returned 19.6% over the past year.
Long-Term Price Volatility Vs. Market
How volatile is Biocept's share price compared to the market and industry in the last 5 years?
Simply Wall St News
3 weeks ago | Simply Wall StBiocept, Inc. (NASDAQ:BIOC): Is Breakeven Near?
2 months ago | Simply Wall StIs Biocept (NASDAQ:BIOC) In A Good Position To Invest In Growth?
6 months ago | Simply Wall StWe Think Biocept (NASDAQ:BIOC) Needs To Drive Business Growth Carefully
Is Biocept undervalued compared to its fair value and its price relative to the market?
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate BIOC's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate BIOC's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: BIOC is unprofitable, so we can't compare its PE Ratio to the US Biotechs industry average.
PE vs Market: BIOC is unprofitable, so we can't compare its PE Ratio to the US market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate BIOC's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: BIOC is good value based on its PB Ratio (3.4x) compared to the US Biotechs industry average (4.2x).
How is Biocept forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: BIOC is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2%).
Earnings vs Market: BIOC is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: BIOC's is expected to become profitable in the next 3 years.
Revenue vs Market: BIOC's revenue (41.1% per year) is forecast to grow faster than the US market (10.2% per year).
High Growth Revenue: BIOC's revenue (41.1% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if BIOC's Return on Equity is forecast to be high in 3 years time
How has Biocept performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: BIOC is currently unprofitable.
Growing Profit Margin: BIOC is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: BIOC is unprofitable, and losses have increased over the past 5 years at a rate of 10.3% per year.
Accelerating Growth: Unable to compare BIOC's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: BIOC is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-10.3%).
Return on Equity
High ROE: BIOC has a negative Return on Equity (-119.06%), as it is currently unprofitable.
How is Biocept's financial position?
Financial Position Analysis
Short Term Liabilities: BIOC's short term assets ($28.8M) exceed its short term liabilities ($10.1M).
Long Term Liabilities: BIOC's short term assets ($28.8M) exceed its long term liabilities ($1.3M).
Debt to Equity History and Analysis
Debt Level: BIOC's debt to equity ratio (1%) is considered satisfactory.
Reducing Debt: BIOC's debt to equity ratio has reduced from 72.1% to 1% over the past 5 years.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: BIOC has less than a year of cash runway based on its current free cash flow.
Forecast Cash Runway: BIOC has less than a year of cash runway if free cash flow continues to reduce at historical rates of 11% each year
What is Biocept current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate BIOC's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate BIOC's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if BIOC's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if BIOC's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of BIOC's dividend in 3 years as they are not forecast to pay a notable one for the US market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Mike Nall (57 yo)
Mr. Michael W. Nall, also known as Mike, has been the Chief Executive Officer and President at Biocept, Inc. since August 26, 2013. Mr. Nall has over 30 years of leadership experience in healthcare sales, ...
CEO Compensation Analysis
Compensation vs Market: Mike's total compensation ($USD1.22M) is above average for companies of similar size in the US market ($USD533.86K).
Compensation vs Earnings: Mike's compensation has increased whilst the company is unprofitable.
|CEO, President & Director||7.42yrs||US$1.22m||0.0031% |
|CFO, Senior VP of Operations & Corporate Secretary||4.5yrs||US$826.51k||0.0022% |
|24yrs||no data||no data|
|Director of Technology Development||3.33yrs||no data||no data|
|General Counsel and Compliance & Privacy Officer||3.25yrs||no data||no data|
|Vice President of Strategy & Corporate Communications||4.25yrs||no data||no data|
|Senior Vice President of Corporate Development||no data||no data||no data|
|Senior Director of Marketing||1yr||no data||no data|
|Senior Director of People & Culture/Facilities||1yr||no data||no data|
|Senior Medical Director||6.08yrs||US$115.22k||no data|
|Senior VP||0.42yr||no data||0.0043% |
Experienced Management: BIOC's management team is considered experienced (3.8 years average tenure).
|CEO, President & Director||7.42yrs||US$1.22m||0.0031% |
|Interim Chair & Lead Independent Director||1yr||US$82.25k||0.00057% |
|Independent Director||11yrs||US$67.25k||0.00043% |
|Member of Scientific Advisory Board||no data||US$287.43k||0.0022% |
|Independent Director||0.25yr||no data||no data|
|Chairwoman Emeritus||9.75yrs||no data||no data|
|Independent Director||7.17yrs||US$66.00k||0.00017% |
|Member of Clinical Advisory Board||no data||no data||no data|
|Independent Director||10.25yrs||US$64.75k||0.0024% |
Experienced Board: BIOC's board of directors are considered experienced (8.9 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have been substantially diluted in the past year, with total shares outstanding growing by 217.3%.
Biocept, Inc.'s company bio, employee growth, exchange listings and data sources
- Name: Biocept, Inc.
- Ticker: BIOC
- Exchange: NasdaqCM
- Founded: 1997
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$71.807m
- Shares outstanding: 13.40m
- Website: https://biocept.com
Number of Employees
- Biocept, Inc.
- 9955 Mesa Rim Road
- San Diego
- United States
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|BIOC||NasdaqCM (Nasdaq Capital Market)||Yes||Common Stock||US||USD||Feb 2014|
|B002||BST (Boerse-Stuttgart)||Yes||Common Stock||DE||EUR||Feb 2014|
|B003||DB (Deutsche Boerse AG)||Yes||Common Stock||DE||EUR||Feb 2014|
Biocept, Inc., an early stage molecular oncology diagnostics company, develops and commercializes proprietary circulating tumor cell and circulating tumor DNA assays utilizing a standard blood sample. The ...
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/01/17 00:28|
|End of Day Share Price||2021/01/15 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.